{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:23:06Z","timestamp":1775128986113,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Paediatric Respiratory Reviews"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.prrv.2006.04.198","type":"journal-article","created":{"date-parts":[[2006,6,7]],"date-time":"2006-06-07T03:34:33Z","timestamp":1149651273000},"page":"S215-S219","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S1","title":["The pharmacologic approach to airway clearance: Mucoactive agents"],"prefix":"10.1016","volume":"7","author":[{"given":"Bruce K.","family":"Rubin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prrv.2006.04.198_bib1","series-title":"The Pediatric Lung","first-page":"155","article-title":"Mucoactive agents: old and new","author":"Rubin","year":"1997"},{"key":"10.1016\/j.prrv.2006.04.198_bib2","series-title":"Therapy for Mucus Clearance Disorders. Biology of the Lung Series, Claude Lenfant (NIH) Executive editor","year":"2004"},{"key":"10.1016\/j.prrv.2006.04.198_bib3","first-page":"341","article-title":"Double-blind, placebo-controlled clinical evaluation of guaimesal in outpatients","volume":"11","author":"Jager","year":"1989","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.prrv.2006.04.198_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1378\/chest.92.4.679","article-title":"Lack of effect of hydration on sputum production in chronic bronchitis","volume":"92","author":"Shim","year":"1987","journal-title":"Chest"},{"key":"10.1016\/j.prrv.2006.04.198_bib5","doi-asserted-by":"crossref","unstructured":"Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev. 2005. CD001506.","DOI":"10.1002\/14651858.CD001506.pub2"},{"key":"10.1016\/j.prrv.2006.04.198_bib6","doi-asserted-by":"crossref","unstructured":"Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev. 2002. CD002996.","DOI":"10.1002\/14651858.CD002996"},{"key":"10.1016\/j.prrv.2006.04.198_bib7","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(01)06412-1","article-title":"Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial","volume":"358","author":"Suri","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2006.04.198_bib8","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1183\/09031936.93.06091243","article-title":"No added benefit from nebulized amiloride in patients with cystic fibrosis","volume":"6","author":"Graham","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.prrv.2006.04.198_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/ppul.1098","article-title":"Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study","volume":"32","author":"Noone","year":"2001","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2006.04.198_bib10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/ppul.20192","article-title":"Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1\/phase 2 multicenter study in mild to moderate cystic fibrosis","volume":"39","author":"Deterding","year":"2005","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2006.04.198_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1165\/rcmb.2003-0345OC","article-title":"MUC5AC and MUC5B mucins are decreased in cystic fibrosis airway secretions","volume":"31","author":"Henke","year":"2004","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.prrv.2006.04.198_bib12","series-title":"Cilia, Mucus and Mucociliary Interactions","first-page":"333","article-title":"DNA and actin filament ultrastructure in cystic fibrosis sputum","author":"Tomkiewicz","year":"1998"},{"key":"10.1016\/j.prrv.2006.04.198_bib13","series-title":"Chapter 7 in Airway secretion: Physiological Bases for the Control of Mucus Hypersecretion","first-page":"283","article-title":"Mucus rheology: Relationship with transport","author":"King","year":"1994"},{"key":"10.1016\/j.prrv.2006.04.198_bib14","first-page":"254","article-title":"Mucociliary transport in vivo and in vitro. Relations to sputum properties in chronic bronchitis","volume":"61","author":"Puchelle","year":"1980","journal-title":"Eur J Respir Dis"},{"key":"10.1016\/j.prrv.2006.04.198_bib15","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ppul.1950100415","article-title":"Recurrent respiratory infections in a child with fucosidosis: Is the mucus too thin for effective transport?","volume":"10","author":"Rubin","year":"1991","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.prrv.2006.04.198_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0149-2918(00)88479-9","article-title":"Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials","volume":"22","author":"Grandjean","year":"2000","journal-title":"Clin Ther"},{"key":"10.1016\/j.prrv.2006.04.198_bib17","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/S0140-6736(05)66456-2","article-title":"Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial","volume":"365","author":"Decramer","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.prrv.2006.04.198_bib18","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1164\/ajrccm.153.2.8564129","article-title":"Effect of rhDNase on airflow obstruction and mucociliary clearance in cystic fibrosis","volume":"153","author":"Laube","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2006.04.198_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1056\/NEJM199409083311003","article-title":"Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis","volume":"331","author":"Fuchs","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prrv.2006.04.198_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/(SICI)1099-0496(199901)27:1<3::AID-PPUL2>3.0.CO;2-A","article-title":"Who will benefit from DNase?","volume":"27","author":"Rubin","year":"1999","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.prrv.2006.04.198_bib21","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1164\/ajrccm.157.3.9703059","article-title":"Improved clearability of cystic fibrosis sputum with dextran treatment in vitro","volume":"157","author":"Feng","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.prrv.2006.04.198_bib22","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1620\/tjem.150.51","article-title":"Effect of oral salbutamol on mucociliary clearance mechanisms in the lungs","volume":"150","author":"Isawa","year":"1986","journal-title":"Tohoku J Experimental Med"},{"key":"10.1016\/j.prrv.2006.04.198_bib23","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1152\/jappl.1985.58.6.1776","article-title":"Clearance of mucus by simulated cough","volume":"58","author":"King","year":"1985","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.prrv.2006.04.198_bib24","doi-asserted-by":"crossref","unstructured":"Hite RD, Seeds MC, Jacinto RB, Balasubramanian R, Waite M, Bass D. Hydrolysis of surfactant-associated phosphotidylcholine by mammalian secretory phospholipases A2. Am J Physiol 1998: 275 (Lung Cell Mol Physiol 19): L740\u2013L747.","DOI":"10.1152\/ajplung.1998.275.4.L740"},{"key":"10.1016\/j.prrv.2006.04.198_bib25","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1001\/jama.278.17.1426","article-title":"Effects of aerosolized surfactant in patients with stable chronic bronchitis. A prospective randomized controlled trial","volume":"278","author":"Anzueto","year":"1997","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.prrv.2006.04.198_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1164\/ajrccm\/145.3.548","article-title":"Effect of indomethacin on bronchorrhea in patients with chronic bronchitis, diffuse panbronchiolitis, or bronchiectasis","volume":"145","author":"Tamaoki","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.prrv.2006.04.198_bib27","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/thx.49.6.545","article-title":"Effect of long term treatment with oxitropium bromide on airway secretion in chronic bronchitis and diffuse panbronchiolitis","volume":"49","author":"Tamaoki","year":"1994","journal-title":"Thorax"},{"key":"10.1016\/j.prrv.2006.04.198_bib28","first-page":"129","article-title":"A global perspective on macrolide use","volume":"58","author":"Shinkai","year":"2005","journal-title":"Japanese J Antibiotics"},{"key":"10.1016\/j.prrv.2006.04.198_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/01.cpm.0000187294.53696.c0","article-title":"Immunomodulatory effects of macrolide antibiotics","volume":"12","author":"Shinkai","year":"2005","journal-title":"Clin Pulm Med"},{"key":"10.1016\/j.prrv.2006.04.198_bib30","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ppul.1076","article-title":"Anti-inflammatory effects of macrolides in lung disease","volume":"31","author":"Jaff\u00e9","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1016\/j.prrv.2006.04.198_bib31","series-title":"Antibiotics as Anti-inflammatory and Immunomodulatory Agents","year":"2004"}],"container-title":["Paediatric Respiratory Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054206002454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526054206002454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,7]],"date-time":"2023-05-07T17:00:26Z","timestamp":1683478826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526054206002454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":31,"alternative-id":["S1526054206002454"],"URL":"https:\/\/doi.org\/10.1016\/j.prrv.2006.04.198","relation":{},"ISSN":["1526-0542"],"issn-type":[{"value":"1526-0542","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}